Vol 5, Supplement 6 (November 2016): Translational Cancer Research


Glioblastoma radiosensitization by pimozide
Barbara H. Rath, Kevin Camphausen, Philip J. Tofilon
MLK4 activates the NF-κB network to drive mesenchymal transition in glioblastoma
Leonie M. Quinn, Ross D. Hannan
Mesenchymal stromal cells and interferon α (IFNα) in cancer immunotherapy
Diana Saleiro, Sara G. Radecki, Leonidas C. Platanias
Rethinking clinical trial design: maximizing the results from each clinical trial participant
Aaron Etra, Charles L. Shapiro
INTEGRATE phase II trial: regorafenib vs. placebo in pretreated metastatic gastric cancer patients—is there anything new?
Marco Puzzoni, Laura Demurtas, Valeria Pusceddu, Mario Scartozzi
Hedgehog signaling in colorectal cancer: a spiny issue gets smoothened
Melania Scarpa, Marco Scarpa
An ace in the hole for hepatocellular carcinoma: yttrium-90 radioembolization
Giovanni Battista Levi Sandri, Giuseppe Maria Ettorre
New insights into the mechanisms of EZH2’s promotion of oncogenesis
David M. Dorfman, Xuejun Tian
Is there still an open window in metastatic castration resistant prostate cancer immunotherapy horizon?
Chiara Ciccarese, Giampaolo Tortora, Rodolfo Montironi, Francesco Massari
Risk of contralateral breast cancer amongst BRCA1/2 mutation carriers
Narendra Nath Basu, D. Gareth Evans
Determination of the optimal screen interval in low-dose CT lung cancer screening: are we there yet?
Marjolein A. Heuvelmans, Matthijs Oudkerk
Prostaglandin E2 plays a major role in glioma resistance and progression
Lisa Oliver, Christophe Olivier, François M. Vallette
Information-dense analysis for information-dense understanding
Nikola A. Ivica, Mandeep Kaur, Guangan Hu, Jianzhu Chen
Thriving where others have faltered—a critical appraisal of the role of patient factors versus treatment effect in JCOG0605 trial in relapsed small cell lung cancer
Nikita T. Patel, Taofeek K. Owonikoko
The use of malaria glycosaminoglycan to block cancers—lessons from the human placenta
Evdokia Dimitriadis
A genomic analysis of large cell neuroendocrine carcinoma versus small cell lung cancer: which is which?
Justine N. McCutcheon, Xiaoliang Zhao, Giuseppe Giaccone
Pancreatic cancer cell invasion: mesenchymal switch or just hitchhiking?
Rémi Samain, Christine Jean, Corinne Bousquet
Subventricular zone microenvironment protects glioblastoma cells from radiotherapy cytotoxicity: role of the chemokine CXCL12
Roberto Würth, Tullio Florio
Sleeve lobectomy or pneumonectomy for non-small cell lung cancer? Searching for an optimal balance between oncological, surgical and functional results
Filippo Lococo, Giacomo Cusumano, Stefano Margaritora, Marco Alifano, Giovanni Leuzzi, Massimiliano Paci
The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies
Keith T. Schmidt, William D. Figg
The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals
Ming-Lung Yu, Chung-Feng Huang
Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy
Roberta Zappasodi, Taha Merghoub
Role of adaptive randomization in developing novel therapies for patients with breast cancer
Robert S. Meehan, Alice P. Chen, James H. Doroshow
Resistance mechanisms to PD-1 inhibition in melanoma
Raphael Brandao, Patrick A. Ott
Advances in molecular genetics of early-stage urothelial carcinoma
Chien-Feng Li, Wen-Jeng Wu, Yow-Ling Shiue
Moving from immune phenotyping of colorectal cancer to mechanistic insights on aspirin use
Halei C. Benefield, John A. Baron, Til Stürmer, Melissa A. Troester
Interplay between MMP-8 and TGF-β1 and its role in regulation of epithelial to mesenchymal transition in hepatocellular carcinoma
Shaoyu Zhou, James E. Klaunig


Is microRNA expression profile in prostate cancer dependent on clinicopathologic stage or cell subtype?
Karthik V. Giridhar, Manish Kohli, Liang Wang
Cisplatin, etoposide, and irinotecan for relapsed small-cell lung cancer
Angel Qin, Gregory P. Kalemkerian
Turning the concept of synthetic lethality on its head
Eileen E. Parkes, Richard D. Kennedy
Dealing with complexity: prognostic implications of karyotype and mutations in chronic lymphocytic leukemia
Nicole R. Grieselhuber, Justin M. Asquith, Leslie A. Andritsos
Thoracoscopic surgery for lung cancer without interruption of anti-platelet agents: is it really safe?
Katsuhiro Okuda, Ryoichi Nakanishi
Is the ColDx assay a valid prognostic marker for stage II colon cancer?
Jessica Felton, Jean-Pierre Raufman
Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better
Ahmad Awada, Nicolas Penel, Nuria Kotecki
Identifying ADP-ribosylation targets by chemical genetics
Aswin Mangerich, Matthias Altmeyer
Implications of the lymph nodal ratio in resected N1 non-small cell lung cancer
Vivek Verma, Steven H. Lin
Predicting disease recurrence in stage II colon cancer: expression signatures and other biomarkers
Klaus-Peter Janssen
Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer
Sacha I. Rothschild
Unraveling epigenetic regulation of epithelial mesenchymal transition
Rattiyaporn Kanlaya, Visith Thongboonkerd
Biomarker guided treatment of advanced non-small cell lung cancer: does feasibility translate to improvements in patient care?
Abdulaziz Al Farsi, Peter Ellis
G-protein coupled receptor PAR1 is overexpressed in glioma progenitor cells
Rachel Bar-Shavit, Jeetendra Kumar Nag, Sorina Grisaru-Granovsky, Beatrice Uziely
Xist at the edge: silencing at the nuclear periphery extends to X inactivation
Justin Demmerle, Lothar Schermelleh
Genetic and epigenetic alterations in urothelial carcinoma
Hon-Yi Lin, Michael W. Y. Chan
Loss of LARP4B, an early event in the tumorigenesis of brain cancer?
Sarah Blagden, Cornelius Schneider, Utz Fischer
A vicious cycle of metabolic interaction between leukemia stem cells and adipose tissues: implications in cachexia and drug resistance
Yi-Qing Li, Pan-Pan Liu, Peng Huang
miRNA profile as a predictor of response to chemoradiation therapy for esophageal squamous cell carcinoma
Kazuto Harada, Dilsa Mizrak Kaya, Yusuke Shimodaira, Shumei Song, Hideo Baba, Jaffer A. Ajani
JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function
Theodoros Karantanos, Vassiliki A. Boussiotis
AKT inhibition: a bad AKT inhibitor in liver injury and tumor development?
Anna Joy, Burt Gary Feuerstein


Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours?
Subotheni Thavaneswaran, Jeremy Shapiro, Eva Segelov
Molecular cross-talk between the liver and white adipose tissue links excessive noURIshment to hepatocellular carcinoma
Alexandra A. Roberts, Lionel W. Hebbard
Lung cancer screening: screening frequency and lung cancer risk
Renee L. Manser
Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer
Nathaniel J. Myall, Heather A. Wakelee
Contemporary management of renal angiomyolipomas
Amy Lim, E. Jason Abel
MET-inhibitors meet MET mutations in lung cancer
Nagio Takigawa
Combination chemotherapy for relapsed small-cell lung cancer—perspective on mechanisms of chemoresistance
Gerhard Hamilton, Barbara Rath
MicroRNAs as novel elements in personalized radiotherapy
Simone Moertl, Lisa Mutschelknaus, Theresa Heider, Michael J. Atkinson
Perspective on targeting salt-inducible kinase 2 (SIK2) in ovarian cancer metastasis
Nathaniel Jensen, Hiu Wing Cheung
Protease-activated receptor 1 (PAR1): a promising target for the treatment of glioblastoma?
Vitor Hugo de Almeida, Robson Q. Monteiro
Neoadjuvant chemotherapy versus chemoradiation for esophageal cancer: no survival difference does not mean no differences
Jose Mario Pimiento, Sarah E. Hofffe, Khaldoun Almhanna
In vivo cancer metabolism is defined by the nutrient microenvironment
Ilaria Elia, Sarah-Maria Fendt
The p53 orbit in chronic myeloid leukemia: time to move to patient care
Alessandro Morotti, Giovanna Carrà, Sabrina Crivellaro


IL2 based immunotherapies: towards a personalized and curative antitumor response
Nicolle H. Rekers, Veronica Olivo Pimentel, Ala Yaromina, Ludwig Dubois, Philippe Lambin
Immunotherapy of pancreatic cancer—weal and woe
Alexandr V. Bazhin, Jens Werner, Svetlana Karakhanova
The regulation of cancer cell glutamine metabolism
Michael J. Lukey, Richard A. Cerione
Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary
Karen T. Brown, Richard Kinh Do, Mithat Gonen, Anne M. Covey, George I. Getrajdman, Constintinos T. Sofocleous, William R. Jarnagin, Michael I. D’Angelica, Peter J. Allen, Joseph P. Erinjeri, Lynn A. Brody, Stephen B. Solomon, Lawrence H. Schwartz, Ronald P. DeMatteo, Ghassan K. Abou-Alfa
Cancer-like mutations in non-cancer tissue: towards a better understanding of multistep carcinogenesis
Jeffrey D. Krimmel, Jesse J. Salk, Rosa Ana Risques
Targeted attack: mechanisms by which ovarian cancers suppress the immune system
Irina V. Tiper, Tonya J. Webb